NCT02870634View on ClinicalTrials.gov

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

October 30, 2019

Study Completion Date

January 30, 2020

Conditions
Amyotrophic Lateral SclerosisMotor Neuron Disease
Interventions
DRUG

Cu(II)ATSM

copper-containing synthetic small molecule

Trial Locations (2)

2109

Macquarie University, Sydenham

3162

Calvary Health Care Bethlehem, Caulfield

Sponsors
All Listed Sponsors
lead

Collaborative Medicinal Development Pty Limited

INDUSTRY

NCT02870634 - Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND | Biotech Hunter | Biotech Hunter